Mephyton Availability
| Aton Label NDC# | 25010-0405-15 |
| Product | Mephyton® Tab |
| Strength | 5mg |
| Unit per Btl/Pk | 100 scored tablets |
| Wholesaler | Item Number |
|---|---|
| AmerisourceBergen | 5030473 092-767 |
| Bellco Health | 257252 |
| Capitol Whls | 196-680 |
| Cardinal Health | 4030201 |
| Cesar Castillo | 00777-66800 |
| Dakota Drug | 118935 |
| DIK Drug | 008-417 |
| F. W. Kerr | 456763 |
| H. D. Smith | 2140770 |
| Kinray | 061-960 |
| McKesson | 145-8561 |
| McQueary Bros. | 580-775 |
| Miami Luken | 041-681 |
| Morris & Dickson | 825-679 |
| NC Mutual Drug | 102459 |
| Rochester Drug | 42552000 |
| Rx Supply | 143834 |
International Availability
cus@idispharma.com
Phone: +44 (0) 1932 824 123
Fax: +44 (0) 1932 824 323
Canada
Aton products are distributed in Canada by Valeo Pharma, Inc.
Phone: 866-694-0150
Fax: 514-694-0865
Indications
MEPHYTON® (PHYTONADIONE) is indicated in the following coagulation
disorders which are due to faulty formation of factors II, VII, IX, and X when
caused by vitamin K deficiency or interference with vitamin K activity.
MEPHYTON tablets are indicated in: anticoagulant-induced prothrombin
deficiency caused by coumarin or indanedione derivatives; hypoprothrombinemia
secondary to antibacterial therapy; hypoprothrombinemia secondary
to administration of salicylates; hypoprothrombinemia secondary to
obstructive jaundice or biliary fistulas but only if bile salts are administered
concurrently, since otherwise the oral vitamin K will not be absorbed.
Important Safety Information
MEPHYTON (PHYTONADIONE) is contraindicated in patients with hypersensitivity to any component of this medication. An immediate coagulation effect should not be expected after administration. MEPHYTON will not counteract the anticoagulant action of heparin. Phytonadione is not a clotting agent, but overzealous therapy with vitamin K1 may restore conditions which originally permitted thromboembolic phenomena. Dosage should be kept as low as possible, and prothrombin time should be checked regularly. Failure to respond to vitamin K may indicate a congenital coagulation defect or that the condition being treated is unresponsive to vitamin K. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
PLEASE SEE FULL PRESCRIBING INFORMATION.
